Developments in Oral Antiplatelet Agents for the Treatment of Acute Coronary Syndromes: Clopidogrel, Prasugrel, and Ticagrelor.

about

Prasugrel versus clopidogrel in stent-assisted coil embolization of unruptured intracranial aneurysms.The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study.

P2860

Q39269731-2151FE8B-2A8D-495A-851F-FB19DF014E8D Q54627886-7F8801FA-89BF-4CD4-8708-F77E038D2370

P2860

Developments in Oral Antiplatelet Agents for the Treatment of Acute Coronary Syndromes: Clopidogrel, Prasugrel, and Ticagrelor.

Item

http://www.wikidata.org/entity/Q38347336

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Developments in Oral Antiplate ...... el, Prasugrel, and Ticagrelor.

@en

type

Item

label

Developments in Oral Antiplate ...... el, Prasugrel, and Ticagrelor.

@en

prefLabel

Developments in Oral Antiplate ...... el, Prasugrel, and Ticagrelor.

@en

P1476

Developments in Oral Antiplate ...... el, Prasugrel, and Ticagrelor.

@en

P2093

David S Roffman

http://www.w3.org/2001/XMLSchema#string

P2860

ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment el

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials

Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventi

Heart disease and stroke statistics--2014 update: a report from the American Heart Association

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

P304

239-249

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0897190014568383

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25660584

http://www.w3.org/2001/XMLSchema#string

P921

clopidogrel

Developments in Oral Antiplatelet Agents for the Treatment of Acute Coronary Syndromes: Clopidogrel, Prasugrel, and Ticagrelor.

about

P2860

P2860

Developments in Oral Antiplatelet Agents for the Treatment of Acute Coronary Syndromes: Clopidogrel, Prasugrel, and Ticagrelor.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921